Vilket är priset för Clarus Therapeutics Holdings, Inc. (CRXTQ)

Priset för Clarus Therapeutics Holdings, Inc. (CRXTQ) är $0.0014

Vilket är marknadsvärdet för Clarus Therapeutics Holdings, Inc. (CRXTQ)

Marknadsvärdet för Clarus Therapeutics Holdings, Inc. (CRXTQ) är $72.83K

Clarus Therapeutics Holdings, Inc. (CRXTQ) Pris och Marknadsvärde

Clarus Therapeutics Holdings, Inc. is a pharmaceutical enterprise dedicated to developing and marketing oral testosterone replacement therapies across the United States. Its primary offering is JATENZO, an oral soft gel formulation of testosterone undecanoate, prescribed for men suffering from hypogonadism. The company has also entered into licensing agreements, including one with HavaH Therapeutics for androgen treatments targeting inflammatory breast disease and specific types of breast cancer. Additionally, Clarus holds an agreement with The Royal Institution for the Advancement of Learning/McGill University to advance and commercialize McGill's exclusive technology, which is designed to address human conditions associated with CoQ10 deficiencies. Founded in 2003, Clarus Therapeutics Holdings, Inc. is headquartered in Northbrook, Illinois. On September 5, 2022, the company, along with an affiliate, voluntarily sought reorganization under Chapter 11 bankruptcy protection in the U.S. Bankruptcy Court for the District of Delaware.

Pris för CRXTQ	Tillgång B	Marknadsvärdet för B	Resultat
$105,142 $72.83K	NVDA	$5.470T	+7,510,109,620.08%
$85,871.01 $72.83K	AAPL	$4.467T	+6,133,643,404.37%
$80,244.70 $72.83K	GOOG	$4.174T	+5,731,763,880.48%
$71,127.00 $72.83K	MSFT	$3.700T	+5,080,499,879.16%
$54,869.35 $72.83K	AMZN	$2.854T	+3,919,239,097.54%

Pris för CRXTQ

Tillgång B

Marknadsvärdet för B

Resultat

$105,142 $72.83K